Both CSCs and immunosuppressive cells express high levels of PD-L1 and they interact as reviewed in Part 2. This rationalizes the promises of combined anti-CSC strategy and PD-1/PD-L1 blockage in cancer immunotherapy. The gene discussed is PDCD1; the disease is cancer.